Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema.
- DOI
- 10.1167/tvst.10.14.28
- Published
- 2021-12-01
- Container
- Transl Vis Sci Technol
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1167/tvst.10.14.28,
title = {Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema.},
author = {Dugel PU and Khanani AM and Berger BB and Patel S and Fineman M and Jaffe GJ and Kozma-Wiebe P and Heier J.},
year = {2021},
journal = {Transl Vis Sci Technol},
doi = {10.1167/tvst.10.14.28},
url = {https://doi.org/10.1167/tvst.10.14.28}
}RIS
TY - JOUR TI - Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema. AU - Dugel PU AU - Khanani AM AU - Berger BB AU - Patel S AU - Fineman M AU - Jaffe GJ AU - Kozma-Wiebe P AU - Heier J. PY - 2021 JO - Transl Vis Sci Technol DO - 10.1167/tvst.10.14.28 UR - https://doi.org/10.1167/tvst.10.14.28 ER -
APA
PU, D., AM, K., BB, B., S, P., M, F., GJ, J., P, K., & J., H. (2021). Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema.. Transl Vis Sci Technol. https://doi.org/10.1167/tvst.10.14.28
Source records
- europe-pmc · retrieved 2026-09-26T12:01:31.881Z